β抑制剂,血脂质和冠状动脉心脏病
1ICI Pharmaceuticals, Mereside, Macclesfield, Cheshire, England.
Circulation
|September 1, 1990
概括
β抑制剂不会显著改变LDL胆固醇,但可以降低HDL胆固醇. 尽管脂质发生了变化,但它们提供了抗缺血性益处,并降低了心肌梗塞死亡率,特别是在急性事件后.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 高血胆固醇是冠心病的主要危险因素,特别是在50岁以下的人群中.
- 低密度脂蛋白 (LDL) 和高密度脂蛋白 (HDL) 是关键的胆固醇载体,高高密度脂蛋白和低低密度脂蛋白与心脏病风险降低有关.
- 贝塔抑制剂通常用于心血管疾病.
研究的目的:
- 为了评估β抑制剂对血脂度的影响.
- 评估β抑制剂对冠心病风险和心肌梗塞 (MI) 的影响.
- 探索β-阻断剂可能在脂质修饰之外发挥心脏保护作用的机制.
主要方法:
- 分析现有的文献和临床数据,分析β-阻断剂对脂质特征的影响.
- 对检查β-阻断剂在二次和一次性心脏病发作预防中的有效性进行研究的综述.
- 检查贝塔抑制剂对血管系统作用的拟议生化和生理机制.
主要成果:
- β抑制剂不会显著影响总胆固醇或LDL胆固醇,但会使HDL胆固醇降低约10%,特别是非选择性药物.
- β阻塞会增加血甘油三和非常低密度脂蛋白 (VLDL) 的度.
- β阻塞剂通过减少心肌中氧气需求和减少心肌中风后30%的死亡,显示出显著的抗缺血性质.
结论:
- 尽管对HDL和甘油三水平有不良影响,但β抑制剂提供了显著的心血管保护.
- β抑制剂可以抑制动脉瘤斑块的发展,并降低斑块破裂和血栓形成的风险.
- 贝塔抑制剂的心脏保护性益处,特别是在心肌梗塞的二次预防中,超过了它们对血脂的影响.
相关概念视频
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:28Antihypertensive Drugs: Types of β-Blockers
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:26Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...